Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
- PMID: 29107679
- DOI: 10.1016/S1470-2045(17)30683-6
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Abstract
Background: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 (90Y) resin microspheres in patients with hepatocellular carcinoma.
Methods: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative therapy), or hepatocellular carcinoma with two unsuccessful rounds of transarterial chemoembolisation. Patients were randomly assigned (1:1) by a permutated block method with block sizes two and four to receive continuous oral sorafenib (400 mg twice daily) or SIRT with 90Y-loaded resin microspheres 2-5 weeks after randomisation. Patients were stratified according to randomising centre, ECOG performance status, previous transarterial chemoembolisation, and presence of macroscopic vascular invasion. The primary endpoint was overall survival. Analyses were done on the intention-to-treat population; safety was assessed in all patients who received at least one dose of sorafenib or underwent at least one of the SIRT work-up exams. This study has been completed and the final results are reported here. The trial is registered with ClinicalTrials.gov, number NCT01482442.
Findings: Between Dec 5, 2011, and March 12, 2015, 467 patients were randomly assigned; after eight patients withdrew consent, 237 were assigned to SIRT and 222 to sorafenib. In the SIRT group, 53 (22%) of 237 patients did not receive SIRT; 26 (49%) of these 53 patients were treated with sorafenib. Median follow-up was 27·9 months (IQR 21·9-33·6) in the SIRT group and 28·1 months (20·0-35·3) in the sorafenib group. Median overall survival was 8·0 months (95% CI 6·7-9·9) in the SIRT group versus 9·9 months (8·7-11·4) in the sorafenib group (hazard ratio 1·15 [95% CI 0·94-1·41] for SIRT vs sorafenib; p=0·18). In the safety population, at least one serious adverse event was reported in 174 (77%) of 226 patients in the SIRT group and in 176 (82%) of 216 in the sorafenib group. The most frequent grade 3 or worse treatment-related adverse events were fatigue (20 [9%] vs 41 [19%]), liver dysfunction (25 [11%] vs 27 [13%]), increased laboratory liver values (20 [9%] vs 16 [7%]), haematological abnormalities (23 [10%] vs 30 [14%]), diarrhoea (three [1%] vs 30 [14%]), abdominal pain (six [3%] vs 14 [6%]), increased creatinine (four [2%] vs 12 [6%]), and hand-foot skin reaction (one [<1%] vs 12 [6%]). 19 deaths in the SIRT group and 12 in the sorafenib group were deemed to be treatment related.
Interpretation: In patients with locally advanced or intermediate-stage hepatocellular carcinoma after unsuccessful transarterial chemoembolisation, overall survival did not significantly differ between the two groups. Quality of life and tolerance might help when choosing between the two treatments.
Funding: Sirtex Medical Inc.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
-
Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma?Lancet Oncol. 2017 Dec;18(12):1560-1561. doi: 10.1016/S1470-2045(17)30687-3. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107680 No abstract available.
-
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.Lancet Oncol. 2018 Feb;19(2):e68. doi: 10.1016/S1470-2045(18)30026-3. Lancet Oncol. 2018. PMID: 29413469 No abstract available.
-
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.Lancet Oncol. 2018 Feb;19(2):e69. doi: 10.1016/S1470-2045(18)30025-1. Lancet Oncol. 2018. PMID: 29413470 No abstract available.
-
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.Lancet Oncol. 2018 Feb;19(2):e70. doi: 10.1016/S1470-2045(18)30024-X. Lancet Oncol. 2018. PMID: 29413471 No abstract available.
-
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC - Authors' reply.Lancet Oncol. 2018 Feb;19(2):e71. doi: 10.1016/S1470-2045(18)30031-7. Lancet Oncol. 2018. PMID: 29413472 No abstract available.
Similar articles
-
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30. Int J Clin Pract. 2017. PMID: 28758319 Review.
-
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Lancet Gastroenterol Hepatol. 2017. PMID: 28648803 Clinical Trial.
-
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2. Cochrane Database Syst Rev. 2017. PMID: 28281295 Free PMC article. Review.
-
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361969 Clinical Trial.
-
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474. Trials. 2014. PMID: 25472660 Free PMC article. Clinical Trial.
Cited by
-
Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere.Cardiovasc Intervent Radiol. 2024 May 14. doi: 10.1007/s00270-024-03726-9. Online ahead of print. Cardiovasc Intervent Radiol. 2024. PMID: 38744685
-
Enhancing the therapeutic impact of sublethal radiofrequency hyperthermia in malignant solid tumor treatment.Heliyon. 2024 Apr 17;10(8):e29866. doi: 10.1016/j.heliyon.2024.e29866. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38681568 Free PMC article. Review.
-
Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma.J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101404. doi: 10.1016/j.jceh.2024.101404. Epub 2024 Mar 29. J Clin Exp Hepatol. 2024. PMID: 38680618
-
Is ALPPS still appropriate for large or locally advanced hepatocellular carcinoma in an era of targeted agents and immunotherapy?Updates Surg. 2024 Jun;76(3):899-910. doi: 10.1007/s13304-024-01789-4. Epub 2024 Mar 25. Updates Surg. 2024. PMID: 38526694
-
Transarterial Therapy for Hepatocellular Carcinoma Invading the Bile Duct.Interv Radiol (Higashimatsuyama). 2024 Feb 8;9(1):1-12. doi: 10.22575/interventionalradiology.2023-0019. eCollection 2024 Mar 1. Interv Radiol (Higashimatsuyama). 2024. PMID: 38524999 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials